Kv1.3 potassium channel blockade as an approach to insulin resistance

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 3, 2005, Pages 571-579

  Desir, Gary V ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Obesity; Potassium channel

Indexed keywords

AMINO ACID; ANTIDIABETIC AGENT; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; POTASSIUM CHANNEL KV1.3; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; VOLTAGE GATED POTASSIUM CHANNEL;

ADIPOSE TISSUE; CELL MEMBRANE; CLINICAL FEATURE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE METABOLISM; HEALTH CARE COST; HUMAN; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; REVIEW; SKELETAL MUSCLE; UNITED STATES; WILD TYPE;

ANIMALS; DIABETES MELLITUS; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; KV1.3 POTASSIUM CHANNEL;

EID: 21244460358     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.3.571     Document Type: Review

References (67)

1. LILLIOJA S, MOTT DM, HOWARD BV et al.: Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N. Engl. J. Med. (1988) 318:1217-1225.
2. DEFRONZO RA, BONADONNA RC, FERRANNINI E: Pathogenesis of NIDDM. A balanced overview. Diabetes Care (1992) 15:318-368.
3. LILLIOJA S, MOTT DM, SPRAUL M et al.: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N. Engl. J. Med. (1993) 329:1988-1992.
4. WARRAM JH, MARTIN BC, KROLEWSKI AS, SOELDNER JS, KAHN CR: Slow glucose removal rate and hyperinsulinemia precede the development of Type II diabetes in the offspring of diabetic parents. Ann. Intern. Med. (1990) 113:909-915.
5. PESSIN JE, SALTIEL AR: Signaling pathways in insulin action: molecular targets of insulin resistance. J. Clin. Invest. (2000) 106:165-169.
6. SALTIEL AR, KAHN RC: Insulin signalling and the regulation of glucose and tipid metabolism. Nature (2001) 414:799-806.
7. LITHERLAND GJ, HAJDUCH E, HUNDAL HS: Intracellular signalling mechanisms regulating glucose transport in insulin-sensitive tissues (review). Mol. Membr. Biol. (2001) 18:195-204.
8. BRUNING JC, GAUTAM D, BURKS DJ et al.: Role of brain insulin receptor in control of body weight and reproduction. Science (2000) 289:2122-2125.
9. SALTIEL AR, PESSIN JE: Insulin signaling pathways in time and space. Trends Cell Biol. (2002) 12:65-71.
10. FERRANNINI E, BARRETT EJ, BEVILACQUA S, DEFRONZO RA: Effect of fatty acids on glucose production and utilization in man. J. Clin. Invest. (1983) 72:1737-1747.
11. MCGARRY JD: What if Minkowski had been ageusic? An alternative angle on diabetes. Science (1992) 258:766-770.
12. RANDLE PJ, GARLAND PB, HALES CN, NEWSHOLME EA: The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet (1963) 1:785-789.
13. RODEN M, PRICE TB, PERSEGHIN G et al.: Mechanism of free fatty acid-induced insulin resistance in humans. J. Clin. Invest. (1996) 97:2859-2865.
14. DRESNER A, LAURENT D, MARCUCCI M et al.: Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. (1999) 103:253-259.
15. PETERSEN KF, HENDLER R, PRICE T et al.: 13C/31P NMR studies on the mechanism of insulin resistance in obesity. Diabetes (1998) 47:381-386.
16. FEINGOLD KR, SOUED M, STAPRANS I et al.: Effect of tumor necrosis factor (TNF) on lipid metabolism in the diabetic rat. Evidence that inhibition of adipose tissue lipoprotein lipase activity is not required for TNF-induced hyperlipidemia. J. Clin. Invest. (1989) 83:1116-1121.
17. HIGUCHI Y, HERRERA P, MUNIESA P et al.: Expression of a tumor necrosis factor alpha transgene in murine pancreatic beta cells results in severe and permanent insulitis without evolution towards diabetes. J. Exp. Med. (1992) 176:1719-1731.
18. RABINOVITCH A: An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab. Rev. (1998) 14:129-151.
19. HOTAMISLIGIL GS: The role of TNFalpha and TNF receptors in obesity and insulin resistance. J. Intern. Med. (1999) 245:621-625.
20. FLIER JS: Diabetes. The missing link with obesity? Nature (2001) 409:292-293.
21. WEISBERG SP, MCCANN D, DESAI M, ROSENBAUM M, LEIBEL RL, FERRANTE AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. (2003) 112:1796-1808.
22. XU H, BARNES GT, YANG Q et al.: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. (2003) 112:1821-1830.
23. BODEN G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes (1997) 46:3-10.
24. AGUIRRE V, UCHIDA T, YENUSH L, DAVIS R, WHITE MF: The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J. Biol. Chem. (2000) 275:9047-9054.
25. RYDEN M, DICKER A, VAN HARMELEN V et al.: Mapping of early signaling events in tumor necrosis factor-alpha-mediated lipolysis in human fat cells. J. Biol. Chem. (2002) 277:1085-1091.
26. HIROSUMI J, TUNCMAN G, CHANG L et al.: A central role for JNK in obesity and insulin resistance. Nature (2002) 420:333-336.
27. WILLIAMSON R: On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br. Med. J. (1901) 1:760-762.
28. YIN MJ, YAMAMOTO Y, GAYNOR RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature (1998) 396:77-80.
29. KIM JK, KIM YJ, FILLMORE JJ et al.: Prevention of fat-induced insulin resistance by salicylate. J. Clin. Invest. (2001) 108:437-446.
30. HUNDAL RS, PETERSEN KF, MAYERSON AB et al.: Mechanism by which high-dose aspirin improves glucose metabolism in Type 2 diabetes. J. Clin. Invest. (2002) 109:1321-1326.
31. PERSEGHIN G, SCIFO P, DE COBELLI F et al.: Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of Type 2 diabetic parents. Diabetes (1999) 48:1600-1606.
32. KRSSAK M, FALK PETERSEN K, DRESNER A et al.: Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia (1999) 42:113-116.
33. PETERSEN KF, BEFROY D, DUFOUR S et al.: Mitochondrial dysfunction in the elderly: possible role in insulin-resistance. Science (2003) 300:1140-1142.
34. PETERSEN KF, DUFOUR S, BEFROY D, GARCIA R, SHULMAN GI: Impaired mitochondrial activity in the insulin-resistant offspring of patients with Type 2 diabetes. N. Engl. J. Med. (2004) 350:664-671.
35. YAO X, CHANG AY, BOULPAEP EL, SEGAL AS, DESIR GV: Molecular cloning of a glibenclamide-sensitive, voltage-gated potassium channel expressed in rabbit kidney. J. Clin. Invest. (1996) 97:2525-2533.
36. CAHALAN MD, CHANDY KG, GRISSMER S: Potassium Channels in Development, Activation, and Disease in T Lymphocytes. Current Topics in Membranes (1991) 39:357-394.
37. GHANSHANI S, WULFF H, MILLER MJ et al.: Up-regulation of the IKCa1 Potassium Channel during T-cell Activation. Molucular Mechanisms and Functional Consequences. J. Biol. Chem. (2000) 275:37137-37149.
38. LEVITE M, CAHALON L, PERETZ A et al.: Extracellular K(+) and opening of voltage-gated potassium channels activate T cell integrin function: physical and functional association between Kv1.3 channels and beta1 integrins. J. Exp. Med. (2000) 191:1167-1176.
39. MOURRE C, CHERNOVA MN, MARTIN-EAUCLAIRE ME et al.: Distribution in rat brain of binding sites of kaliotoxin, a blocker of Kv1.1 and Kv1.3 alpha-subunits. J. Pharmacol. Exp. Ther. (1999) 291:943-952.
40. JACOB A, HURLEY IR, GOODWIN LO, COOPER GW, BENOFF S: Molecular characterization of a voltage-gated potassium channel expressed in rat testis. Mol. Hum. Reprod. (2000) 6:303-313.
41. ARKETT SA, DIXON J, YANG JN, SAKAI DD, MINKIN C, SIMS SM: Mammalian osteoclasts express a transient potassium channel with properties of Kv1.3. Receptors Channels (1994) 2:281-293.
42. KOMAROVA SV, DIXON SJ, SIMS SM: Osteoclast ion channels: potential targets for antiresorptive drugs. Curr. Pharm. Des. (2001) 7:637-654.
43. WARNTGES S, FRIEDRICH B, HENKE G et al.: Cerebral localization and regulation of the cell volume-sensitive serum- and glucocorticoid-dependent kinase SGK1. Pflugers Arch. (2002) 443:617-624.
44. LANG F, UHLEMANN AC, LEPPLE-WIENHUES A et al.: Cell volume regulatory mechanisms in apoptotic cell death. Herz. (1999) 24:232-235.
45. 22, a potent Kv1.3-specific immunosuppressive polypeptide J. Biol. Chem. (1998) 273(49):32697-32707.
46. FADOOL DA, TUCKER K, PHILLIPS JJ, SIMMEN JA: Brain insulin receptor causes activity-dependent current suppression in the olfactory bulb through multiple phosphorylation of Kv1.3. J. Neurophysiol. (2000) 83:2332-2348.
47. BOWLBY MR, FADOOL DA, HOLMES TC, LEVITAN IB: Modulation of the kv1.3 potassium channel by receptor tyrosine kinases. J. Gen. Physiol. (1997) 110:601-610.
48. XU J, KONI PA, WANG P et al.: The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body weight. Hum. Mol. Genet. (2003) 12:551-559.
49. XU J, KONI PA, WANG P et al.: The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity. Proc. Natl. Acad. Sci. USA (2004) 101:3112-3117.
50. MANCHEM VP, GOLDFINE ID, KOHANSKI RA et al.: A novel small molecule that directly sensitizes the insulin receptor in vitro and in vivo. Diabetes (2001) 50:824-830.
51. BROWN H, KOZLOWSKI R, PERRY H: The importance of ion channels for macrophage and microglial activation in vitro. Glia (1998) 22:94-97.
52. DECOURSEY TE, CHANDY KG, GUPTA S, CAHALAN MD: Voltage-Dependent Ion Channels in T-Lymphocytes. J. Neuroimmunol. (1985) 10:71-95.
53. MATTESON DR, DEUTSCH C: K channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. Nature (1984) 307:468-471.
54. KOO GC, BLAKE JT, SHAH K et al.: Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell. Immunol. (1999) 197:99-107.
55. BEETON C, WULFF H, BARBARIA J et al.: Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl. Acad. Sci. USA (2001) 98:13942-13947.
56. ATTALI B, HONORÉ E, LESAGE F, LAZDUNSKI M, BARHANIN J: Regulation of a major cloned voltage-gated K+ channel from human T lymphocytes. FEBS Lett. (1992) 303:229-232.
57. SZABO I, BOCK J, JEKLE A et al.: A novel potassium channel in lymphocyte mitochondria. J. Biol. Chem. (2005).
58. ZISMAN A, PERONI OD, ABEL ED et al.: Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat. Med. (2000) 6:924-928.
59. WOJTASZEWSKI JF, HIGAKI Y, HIRSHMAN MF et al.: Exercise modulates postreceptor insulin signaling and glucose transport in muscle-specific insulin receptor knockout mice. J. Clin. Invest. (1999) 104:1257-1264.
60. RICHTER FA, DERAVE W, WOJTASZEWSKI JF: Glucose, exercise and insulin: emerging concepts. J. Physiol. (2001) 535:313-322.
61. MU J, BROZINICK JT Jr, VALLADARES O, BUCAN M, BIRNBAUM MJ: A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol. Cell. (2001) 7:1085-1094.
62. THORELL A, HIRSHMAN MF, NYGREN J et al.: Exercise and insulin cause GLUT-4 translocation in human skeletal muscle. Am. J. Physiol. (1999) 277:E733-E741.
63. HAYASHI T, HIRSHMAN MF, DUFRESNE SD, GOODYEAR LJ: Skeletal muscle contractile activity in vitro stimulates mitogen-activated protein kinase signaling. Am. J. Physiol. (1999) 277:C701-C707.
64. MACDONALD PE, HA XF, WANG J et al.: Members of the Kv1 and Kv2 voltage-dependent K(+) channel families regulate insulin secretion. Mol. Endocrinol. (2001) 15:1423-1435.
65. CHUTKOW WA, SAMUEL V, HANSEN PA, PU J et al.: Disruption of Sur2-containing KATP channels enhances insulin-stimulated glucose uptake in skeletal muscle. Proc. Natl. Acad. Sci. USA (2001) 98:11760-11764.
66. WASADA T, YANO T, OHTA M et al.: ATP-sensitive potassium channels modulate glucose transport in cultured human skeletal muscle cells. Endocr. J. (2001) 48:369-375.
67. KALMAN K, PENNINGTON MW, LANIGAN MD et al.: ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J. Biol. Chem. (1998) 273:32697-32707.